Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay

OBJECTIVES: To assess whether a commercially available CE-IVD, ELISA-based surrogate neutralisation assay (cPass, Genscript) provides a genuine measure of SARS-CoV-2 neutralisation by human sera, and further to establish whether measuring responses against the RBD of S was a diagnostically useful pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Murray, Matthew J., McIntosh, Megan, Atkinson, Claire, Mahungu, Tabitha, Wright, Edward, Chatterton, Wendy, Gandy, Michael, Reeves, Matthew B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: W.B. Saunders 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979278/
https://www.ncbi.nlm.nih.gov/pubmed/33753152
http://dx.doi.org/10.1016/j.jinf.2021.03.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979278/
https://www.ncbi.nlm.nih.gov/pubmed/33753152
http://dx.doi.org/10.1016/j.jinf.2021.03.010

Ejemplares similares